Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Anti-Cancer Drugs

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CAD.0000000000000069PMID 24361761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evidence for Ca(2+)-regulated ATP release in gastrointestinal stromal tumors.

  2013cited by this paper
• The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy.

  2012cited by this paper
• One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

  2012cited by this paper
• A method for quantitative analysis of an anticancer drug in human plasma with CE‐ESI‐TOF‐MS

  2011cited by this paper
• Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

  2011cited by this paper
• Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor

  2010cited by this paper
• The role of imatinib plasma level testing in gastrointestinal stromal tumor

  2010cited by this paper
• Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

  2009cited by this paper
• Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications

  2008cited by this paper
• Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors

  2007cited by this paper
• OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.

  2006cited by this paper
• Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

  2006cited by this paper
• Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors

  2006cited by this paper
• METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

  2005cited by this paper
• Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib

  2005cited by this paper
• KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.

  2005cited by this paper
• Active transport of imatinib into and out of cells: implications for drug resistance.

  2004cited by this paper
• Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

  2004cited by this paper
• Imatinib mesylate ( STI 571 ) is a substrate for the breast cancer resistance protein ( BCRP ) / ABCG 2 drug pump

  2004cited by this paper
• Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion

  2004cited by this paper
• Functional consequence of MDR1 expression on imatinib intracellular concentrations.

  2003cited by this paper
• α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients

  2003cited by this paper
• Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.

  2003cited by this paper
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

  2003cited by this paper
• Interaction of Imatinib Mesilate with Human P-Glycoprotein

  2003cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• Water drinking causes a biphasic change in blood composition in humans

  2001cited by this paper
• STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

  2001cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.

  2000cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper
• Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

  1996cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Clinical significance of P-glycoprotein in multidrug resistance malignancies.

  1993cited by this paper
• Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments]

  1993cited by this paper

• Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?

  2023cites this paper
• Liquid chromatography–tandem mass spectrometry for clinical diagnostics

  2022cites this paper
• Direct interaction of the ATP-sensitive K+ channel by the tyrosine kinase inhibitors imatinib, sunitinib and nilotinib.

  2021cites this paper
• Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor

  2019cites this paper
• Translational investigations of novel and current antitumoral therapies in gastrointestinal stromal tumors

  2019cites this paper
• Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes

  2018cites this paper
• CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients

  2017cites this paper
• Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib

  2016cites this paper
• Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour

  2016cites this paper
• Development of protein kinase-responsive photoluminescent probes and cellular regulators of protein phosphorylation

  2016cites this paper
• LC-MS/MS as a tool for TDM services: Where are we?

  2016cites this paper
• Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib

  2015cites this paper
• Secretome protein signature of human gastrointestinal stromal tumor cells.

  2015cites this paper
• Inhibition of CREB Phosphorylation by Conjugates of Adenosine Analogues and Arginine‐Rich Peptides, Inhibitors of PKA Catalytic Subunit

  2015cites this paper
• High-abundant protein depletion strategies applied on dog cerebrospinal fluid and evaluated by high-resolution mass spectrometry

  2015cites this paper
• Functional role of the Ca²⁺-activated Cl⁻ channel DOG1/TMEM16A in gastrointestinal stromal tumor cells.

  2014cites this paper